For nutraceutical, dietary supplement and consumer health brands, claims substantiation is no longer just a regulatory checkbox - it’s a market access requirement.

Under the Federal Trade Commission (FTC), all health-related advertising claims must be supported by competent and reliable scientific evidence (CARSE). This standard is central to:

• FDA clinical trial requirements for dietary supplements (indirectly via FTC enforcement)

• evidence-based nutraceutical claims

• global regulatory strategy for clinical research

Failure to meet this standard can result in enforcement actions, penalties, and loss of consumer trust.

What is FTC CARSE (Competent and Reliable Scientific Evidence)?

The FTC defines CARSE as: Scientific evidence derived from tests, analyses, research, or studies conducted objectively by qualified experts and accepted within the scientific community.

This applies across:

• Dietary supplements

• Functional foods

• Medical nutrition

• Consumer health products

For health-related claims, the FTC expects a high level of substantiation, often including well-designed human clinical trials.

The Missing Piece: What Does “Competent” Actually Mean?

While reliable refers to the quality of evidence, the term competent focuses on:

The people, processes, and systems involved in generating that evidence.

This is where most brands and even experienced sponsors get it wrong.

Because clinical trial design services for nutraceuticals are often evaluated based on:

• Past publications

• Brand reputation

• Cost

Instead of true functional competence in clinical research execution.

Breaking Down “Competence” in Clinical Research

1. Multidisciplinary Expertise (Not Just Investigators)

High-quality biomarker-driven clinical trials require a coordinated ecosystem of:

• Clinical investigators

• Biostatisticians

• Clinical data management teams

• Laboratories

• Project management teams

A single investigator or academic partner is not sufficient to ensure competent clinical trial execution. 

2. Robust Clinical Trial Design and Protocol Development

Effective endpoint selection in clinical trials begins long before execution.

It requires:

• Study synopsis development

• Protocol design aligned with regulatory expectations

• Case report form (CRF) structuring

• IRB-ready documentation

These are not administrative tasks - they are foundational to global clinical trial design.

3. Site Execution and Clinical Operations Excellence

Even the best-designed study can fail due to poor execution.

A competent team ensures:

• High-quality patient recruitment and retention

• Accurate data capture

• Strong site monitoring practices

The role of the Clinical Research Coordinator (CRC) is especially critical in ensuring clinical trial generalizability and data integrity.

4. Laboratory Competence and Data Integrity

For mechanism-driven clinical endpoints, lab quality can make or break a study.

A competent lab must have:

• Certifications (ISO, GLP, CAP)

• SOP-driven processes

• Validated analytical methods

• Strong audit history

Without this, even statistically significant results may fail regulatory scrutiny.

5. Alignment with Global Regulatory Standards

Competence also means designing studies aligned with:

• ICH Good Clinical Practice (GCP) guidelines

• FDA expectations

• EFSA clinical evidence requirements

Modern updates like ICH E6(R3) emphasize:

• Quality by Design

• Risk-based monitoring

• Data integrity systems

Why “Competence” Directly Impacts Claims Substantiation 

FTC enforcement is based on one key principle:

Advertisers must have a reasonable basis for claims before making them.

This means:

• Evidence must exist before marketing

• Evidence must match the specific claim

• Evidence must meet expert expectations in the field

Poorly executed trials even if published may fail CARSE because:

• Endpoints are weak

• Execution is flawed

• Data integrity is questionable

The Role of Clinical Trial Design in FTC Compliance

To meet competent and reliable scientific evidence standards, trials must be:

Scientifically Sound

• Mechanism-driven endpoints

• Relevant biomarkers

• Clear hypothesis

Operationally Strong

• High-quality sites

• Controlled study conditions

• Standardized procedures

Statistically Robust

• Adequate sample size

• Proper controls

• Clinically meaningful outcomes

This is where endpoint selection consulting for clinical trials becomes critical.

Common Mistakes Brands Make in CARSE Compliance

1. Over-Reliance on Single Studies

FTC guidance suggests that one clinical trial may not always be sufficient, especially for strong claims. 

2. Choosing the Wrong CRO Partner

Selecting based on:

• Cost

• Brand name

• Past experience

Instead of:

• Functional expertise

• Trial execution capability

• Regulatory alignment 

3. Weak Endpoint Strategy

Using:

• Subjective endpoints

• Non-validated measures

Instead of:

• mechanism-driven clinical endpoints

• Biomarker-backed outcomes 

4. Misalignment Between Claim and Evidence

FTC requires:

• Evidence to directly support the specific claim made

• Not generic or indirect data

A Smarter Approach: Competence-Led Clinical Development 

At Vedic Lifesciences, we approach CARSE compliance differently:

1. Mechanism-Driven Clinical Strategy

• Focus on biomarker-driven clinical trials

• Prioritize translational clinical research 

2. End-to-End Clinical Trial Design Services

• Protocol development

• Endpoint selection

• Regulatory alignment

3. Cost-Effective Global Execution

• Clinical trials in India for nutraceuticals

• Faster recruitment, lower costs

• High-quality data generation

4. Regulatory-First Thinking

• Designed for FDA and FTC compliance

• Built for global claim substantiation

The Future of Claims Substantiation in Nutraceuticals

The industry is moving toward:

• Stricter FTC enforcement

• Greater reliance on clinical evidence generation services

• Increased demand for global clinical trial execution partners

• Higher scrutiny on data quality and competence 

If your claim fails FTC scrutiny, the issue is rarely just the data.

The real question is:

Was the study done?
Or was it done competently?

Because: Competent science doesn’t just generate data, it generates defensible claims.